REXO1 Inhibitors

REXO1 inhibitors, as currently understood, primarily encompass compounds that indirectly influence the protein's function by interfering with RNA or DNA synthesis, processing, and stability. These molecular entities interact with various steps of RNA and DNA dynamics, given REXO1's role in small ribosomal RNA and ribosomal DNA processing.

Actinomycin D and Cordycepin, for instance, are well-known for their capacity to inhibit RNA synthesis. By halting RNA synthesis, they can inevitably influence the pool of substrates that REXO1 interacts with, thereby impacting its function. Similarly, agents such as Doxorubicin and Daunorubicin intercalate into DNA, which can disrupt the very nucleic acid structures that REXO1 would engage with. On another front, Etoposide and Camptothecin target topoisomerases, enzymes critical for DNA dynamics, indicating a sphere of influence on REXO1's activity due to altered DNA processing. DNA synthesis inhibitors like Aphidicolin and Fludarabine can directly influence the DNA substrates available for REXO1. By interacting with these key components of nucleic acid dynamics, these chemical compounds shed light on the intertwined nature of cellular processes and present a spectrum of molecules that, while not direct inhibitors, can have profound implications on the functional landscape in which REXO1 operates.